Cancer Treatment
-
Histotripsy: FDA Clears Non-Invasive Cancer Treatment, HOPE4LIVER Trial Shows Promising Results
Histotripsy, a non-invasive ultrasound therapy, is now FDA-approved for liver tumors. The HOPE4LIVER trial showed local control rates and safety profiles, but…
-
Dendritic Cell Cancer Vaccines: One FDA Approval, Most Others Still in Trials
Only sipuleucel-T is approved for advanced prostate cancer; private clinics like Immunocine in Mexico sell personalized dendritic cell therapies still in clinical…
-
BMS RYZ101 Meets Phase 3 Goal in Neuroendocrine Tumors After Lutetium-177 Failure
Bristol Myers Squibb reports its actinium-225 therapy met primary endpoint in ACTION-1 trial, offering hope for a narrow group of patients.
-
What Clinical Trials Really Show About Tigilanol Tiglate from the Blushwood Berry
A viral social media post revived interest in the rainforest drug, but current human trials reveal targeted local results rather than a…
-
European Regulators Back Breakthrough Pancreatic Cancer Drug Rasonque
The EMA has recommended approval for daraxonrasib, a daily pill that doubles survival rates for patients with metastatic pancreatic adenocarcinoma.
-
FDA expands Anktiva approval to cover papillary-only bladder cancer, first treatment for this group
The FDA has broadened Anktiva’s use with BCG to include patients with BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer, offering a bladder-preserving option…
-
Jimmy Carter’s Melanoma Treatment Changed Cancer Care, Doctors Say
Rome, October 1 — The mechanics here are straightforward: immunotherapy, a breakthrough in cancer treatment, has generated significant revenue for biotechnology companies,…
-
How Oncotype DX Works: The 21-Gene Recurrence Score Explained
MUNICH, July 17 — A gene expression profiling test that has become a standard tool in breast cancer treatment decisions works by…
-
Oncotype DX Gene Test Spares Many Breast Cancer Patients From Chemotherapy
MADISON, Wisconsin, July 17 — The genomic test Oncotype DX has fundamentally altered the strategic calculus of breast cancer treatment, shifting the…
-
Colorectal cancer is rising in adults under 50 as many patients are told they are too young
INDIANAPOLIS, July 15 — A study published yesterday by researchers at the Indiana University School of Medicine is bringing new urgency to…
-
Immunotherapy harnesses immune system to fight cancer tumors
NEW YORK, July 14 — When James Allison and Tasuku Honjo shared the Nobel Prize in Physiology or Medicine in 2018, they…
-
HDT Bio Takes Glioblastoma Immunotherapy HDT-401 Toward a Phase 1 Trial at McGill
MONTREAL, July 13 — McGill University has announced a new partnership with HDT Bio, a biotechnology firm, to advance clinical trials for…
-
Immunotherapy Side Effects Affect More Than 60% of Patients, MD Anderson Says
WASHINGTON, July 10 — The strategic calculus of cancer treatment is shifting, and with it comes a new set of battlefield risks…
-
FDA Immunotherapy Approvals Reach 156 Since 2011, Cancer Research Institute Reports
WASHINGTON, July 10 — The first checkpoint inhibitor landed in March 2011, a drug called ipilimumab, approved for melanoma. Since then, the…
-
FDA Approves Breyanzi CAR-T Therapy for Relapsed Chronic Lymphocytic Leukemia
MANILA, July 7 — For families across the region watching loved ones battle blood cancers that keep returning, a new treatment option…
-
Owerko Centre Among Sites Sharing Alberta Cancer Foundation’s $35M Trials Fund
CALGARY, July 7 — A major investment announced yesterday is set to transform how quickly families across Alberta, and potentially beyond, can…
-
Modified Vitamin B12 Crosses Blood-Brain Barrier and Targets Glioblastoma in Animal Study
Glioblastoma kills. It kills fast. Most patients get fifteen months, if they’re lucky. Surgery, radiation, chemotherapy — the standard toolkit — rarely…
-
Researchers Use Vitamin B12 to Deliver Glioblastoma Drug Past Blood-Brain Barrier
History is littered with promising cancer treatments that worked beautifully in mice and then fell apart in people. That sobering fact hangs…
-
Virginia Cancer Specialists: 21 Doctors in Top Docs Hall of Fame
FAIRFAX, June 17 — Virginia Cancer Specialists announced that 21 of its physicians have been named to the Washingtonian “Top Doctors” Hall…
-
Johann Lafer Says Lymph Nodes Are Shrinking After Four Chemotherapy Cycles
HAMBURG — The lymph nodes are shrinking. For Johann Lafer, that is the difference between a treatment that is working and one…
-
Johann Lafer Says Lymphoma Cannot Be Cured After Early Chemotherapy Gains Shrank His Lymph Nodes
Understanding Lafer’s Condition Lafer was diagnosed with an indolent, low-grade, non-Hodgkin lymphoma earlier this year, with the diagnosis being made public in…
-
Roche Launches 7-Minute Lung Cancer Injection in India to Replace Hours-Long IV Infusions
For lung cancer patients in India, the treatment chair has been a fixed point — hours of intravenous drip, hospital waits, repeated…
-
Roche Brings 7-Minute Lung Cancer Shot to India at About ₹3.7 Lakh a Dose
MUMBAI — For lung cancer patients in India, a treatment that once meant sitting for an hour or more with an IV…
-
Roche Launches Subcutaneous Lung Cancer Immunotherapy in India
MUMBAI — The needle goes in. Seven minutes later, it’s over. That is the new reality for lung cancer patients in India,…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
New Studies Show Immunotherapy Gaining Ground in Lung, Prostate and Childhood Cancers
-
Why Broad RAS-Targeting Drugs Mark a Turning Point in Treating Pancreatic Cancer
-
How At-Home Igalmi Differs From Traditional Treatments for Schizophrenia and Bipolar Agitation
-
Boron Neutron Capture Therapy Faces US Coverage Hurdles Over Cost and Data Gaps
-
FDA Proposes Slashing Companion Diagnostic Fees From $636,732 to $28,653
-
Biocon’s Pebrilzo FDA Approval Cements Its Role in Affordable Cancer Care
-
Navigating 7% Mortgage Rates: Strategies for Buying a Home Now
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992
























